Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319742 | 0.82 | HDAC2 (0.36) | ROCK1HDAC2 | |
| SCHEMBL31115874 | 0.80 | MAPT (0.33) | HDAC2L3MBTL1 | |
| SCHEMBL122032 | 0.77 | KIT (0.36) | HDAC2L3MBTL1JAK2JAK1 | |
| SCHEMBL1436338 | 0.77 | PSD (0.34) | HDAC2L3MBTL1 | |
| SCHEMBL1197473 | 0.77 | L3MBTL1 (0.51) | HDAC2L3MBTL1 | |
| SCHEMBL26017061 | 0.74 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL177295 | 0.74 | L3MBTL1 (0.41) | HDAC2L3MBTL1 | |
| SCHEMBL26066445 | 0.74 | KDM4E (0.32) | L3MBTL1 | |
| SCHEMBL3321417 | 0.74 | PDK2 (0.36) | HDAC2L3MBTL1JAK2JAK1 | |
| SCHEMBL15463236 | 0.73 | LMNA (0.41) | FADS1ROCK1SCD5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | FADS1 3402/4885ROCK1 3409/4885HDAC2 694/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | FADS1 3334/4885ROCK1 3936/4885HDAC2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.